Enhancing Lives Through Breakthrough Technology



At Neurolief, we’re committed to bringing relief to people suffering from mental health and neurological disorders. As pioneers in mental healthcare, we’ve developed the world’s first and only non-invasive, multi-channel brain neuromodulation system. This system concurrently neuromodulates major neural pathways in the head, thereby affecting brain regions involved in the regulation of mood and pain. Neurolief technology is approved by the FDA (USA), CE (Europe), and PMDA (Japan) for the treatment of migraine.

Neurolief has successfully completed its pivotal clinical study in the treatment of major depression and is now seeking regulatory approval for this innovative therapy.

Our team

Our executive team comprises industry-leading experts with extensive experience and a stellar track record in neuroscience, neuromodulation technology, and the neurotech industry. 


Amit Dar

Founder & CTO

An expert in neuromodulation, Amit is an accomplished entrepreneur and former Director of Global Research & Development at Bioness Neuromodulation. He also served as VP of Research & Development at NESS, where he spearheaded the development and successful global market launch of groundbreaking neuromodulation technologies now utilized by hundreds of thousands of patients worldwide.

Scott Drees

CEO

A pioneer in the field of neuromodulation, Scott was the Founder & CEO of Nuvectra & QiG Group and the worldwide commercialization leader at ANSI & St. Jude Medical Neuro. Mr. Drees also led significant early-stage company development and go-to-market strategies in the Spinal Cord, Deep Brain, Vagus, Sacral & Peripheral Nerve stimulation markets.

Anthony Borowicz

CFO

Anthony has 40 years of experience of medical device industry with demonstrated history of creating shareholder value. Former SVP of Strategy, Corporate Development & Investor Relations for Integer Holdings. Held previous Finance & CFO roles for public & private companies

Steve Beller

CCO

Steve is an experienced commercial leader with over 20 years in the neuromodulation industry and in the psychiatric/mental health market. Prior to joining Neurolief he was the US commercial leader for Nexstim, a TMS company, and previously he was Sr. VP of Sales for St. Jude Medical/Abbot Neuromodulation.

Ron Belson

VP R&D and Eng

Former Director of Product Management at 3M with management positions in Damek & Aran R&D, Ron has extensive experience in the full cycle of product development and transfer to production

Michal Kedar-datel

VP  Clinical & Regulatory Affairs

Former worldwide Clinical Compliance Program Manager at Medtronic and Clinical Trials Manager at Given Imaging, Michal has vast experience in leading worldwide clinical trials and regulatory processes

Amir Cohen

Director Clinical Development

Former Clinical Manager and Product Manager at Bioness Neuromodulation, Amir has extensive experience in neuromodulation technologies and its implementation in clinical practice.

Get in Touch with Us!